Literature DB >> 2015922

Surgical treatment of ductal pancreatic carcinoma.

F P Gall1, H Kessler, P Hermanek.   

Abstract

Among 587 patients with ductal pancreatic carcinoma who were examined between 1969 and 1987, 260 (44.3%) had distant metastases at the time of diagnosis. Tumour resections, mostly subtotal duodenopancreatectomies, were performed in 138 patients (23.5% of all patients, or 39.8% of all patients without distant metastases); in 91 patients the resection was for cure (R0). Operative mortality following tumour resection was 6% for all patients. The age-corrected 5-year survival rate was 2.9% for all patients and 16% where the resection was curative; of these 46% were in Stages I and II and 6% in Stage III. In non-curative resections, the median survival time was 7.2 months, which was significantly longer than the 3.4 months following bypass operation. Cure for pancreatic carcinoma can be achieved only through surgery, and a negative attitude towards surgery must be resisted.

Entities:  

Mesh:

Year:  1991        PMID: 2015922

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  15 in total

1.  Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas.

Authors:  W Meyer; C Jurowich; M Reichel; B Steinhäuser; P H Wünsch; C Gebhardt
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

2.  Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).

Authors:  J P Neoptolemos; P Baker; H Beger; K Link; P Pederzoli; C Bassi; C Dervenis; H Friess; M Büchler
Journal:  Int J Pancreatol       Date:  1997-04

Review 3.  Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy.

Authors:  S P Povoski; M S Karpeh; K C Conlon; L H Blumgart; M F Brennan
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

Review 4.  Controversial issues in the management of pancreatic cancer: Part Two. A debate held at St Mary's Hospital, London on 18 November 1993.

Authors:  G Glazer; C Coulter; M E Crofton; W M Gedroyc; C D Johnson; C N Mallinson; R C Russell; M L Steer; J A Summerfield; R C Williamson
Journal:  Ann R Coll Surg Engl       Date:  1995-05       Impact factor: 1.891

5.  Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.

Authors:  J P Neoptolemos; D D Stocken; J A Dunn; J Almond; H G Beger; P Pederzoli; C Bassi; C Dervenis; L Fernandez-Cruz; F Lacaine; J Buckels; M Deakin; F A Adab; R Sutton; C Imrie; I Ihse; T Tihanyi; A Olah; S Pedrazzoli; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Ann Surg       Date:  2001-12       Impact factor: 12.969

6.  An audit of pathology lymph node dissection techniques in pylorus preserving Kausch-Whipple pancreatoduodenectomy specimens.

Authors:  I H Chaudhry; F Campbell
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

7.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

8.  Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Chandrajit P Raut; Jennifer F Tseng; Charlotte C Sun; Huamin Wang; Robert A Wolff; Christopher H Crane; Rosa Hwang; Jean-Nicolas Vauthey; Eddie K Abdalla; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

9.  Ductal adenocarcinoma of the pancreas. Histopathological features and prognosis.

Authors:  A Tannapfel; C Wittekind; G Hünefeld
Journal:  Int J Pancreatol       Date:  1992-10

10.  Occult tumor cells in lymph nodes as a predictor for tumor relapse in pancreatic adenocarcinoma.

Authors:  Peter Scheunemann; Nikolas H Stoecklein; Alexander Rehders; Minu Bidde; Sylvia Metz; Matthias Peiper; Claus F Eisenberger; Jan Schulte Am Esch; Wolfram T Knoefel; Stefan B Hosch
Journal:  Langenbecks Arch Surg       Date:  2007-08-18       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.